Business Wire

NY-IFF

10.2.2020 22:17:12 CET | Business Wire | Press release

Share
IFF Named to Barron’s 100 Most Sustainable Companies List for Third Consecutive Year

Regulatory News:

IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced its third consecutive recognition on Barron’s 100 Most Sustainable Companies List, an index first launched in February 2018. It joins the ranks of 99 other leading U.S. companies assessed for environmental, social and corporate governance practices.

“We are delighted to once again be named to Barron’s prestigious sustainability index,” said Andreas Fibig, IFF Chairman & CEO. “This recognition is further testament to our passionate employees across the world and IFF’s commitment to global sustainability leadership, as we redefine how we live in and care for the resources of our world.”

In partnership with U.S. based investment advisory firm Calvert Research and Management, the Barron’s list was compiled by evaluating the 1000 largest publicly traded companies against hundreds of ESG performance indicators. These indicators, which address topics such as workplace diversity, data security and greenhouse-gas emissions, were then used to rank each company’s performance in five key constituencies: shareholders, employees, customers, community and the planet.

IFF’s EVP, Chief Global Scientific & Sustainability Officer Dr. Gregory Yep said, “This is a fantastic achievement for IFF, where sustainability priorities remain deeply connected to the overall success of our organization. As IFF continues to grow and evolve, we remain focused on opportunities to create a smarter, greener and more viable company positioned to protect our planet and the well-being of future generations.”

Through 2019, the Company:

  • Continues to execute on its environmental goals focused on emission reductions, zero waste to landfill and water stewardship, known collectively as “EcoEffective+”
  • Signed the United Nations’ “Business Ambition for 1.5°C – Our Only Future” pledge, a campaign to put more aggressive science-based goals into action to help limit global temperature rise to 1.5 degrees Celsius
  • Received Double-A distinction from CDP, including recognition on CDP’s A List for Climate Change (fifth consecutive) and Water Security (second consecutive), reaffirming IFF’s global leadership in environmental responsibility
  • Opened the industry’s largest solar array at its Union Beach, New Jersey property, which is expected to generate over nine million kilowatt hours annually, powering IFF’s R&D facility and returning any excess energy to the grid
  • Deepened its commitment to diversity and inclusion by signing onto the United Nations Global LGBTI Standards of Conduct for Business (“the Standards”), joining 250 of the world’s largest companies in the pledge to tackle discrimination against lesbian, gay, bisexual, transsexual and intersex (LGBTI) people in the community, workplace and marketplace
  • Solidified its commitment to gender parity and women’s empowerment by pledging to adopt the United Nations Women’s Empowerment Principles (“the Principles”), a set of seven tenets to advance and empower women and provide equal treatment in the workplace, marketplace and community
  • Received the 2019 “Industry Mover” award from SAM, a subsidiary of RobecoSAM which specializes in providing ESG data, benchmarks and ratings, for the Company’s top-scoring performance in economic, social and environmental categories
  • Pledged to achieve a full global EDGE certification in 2020, to advance the Company’s certification from the Economic Dividends for Gender Equality (EDGE) for its business in the United States
  • Installed a series of nesting platforms to support the conservation of ospreys, a North American raptor species challenged by environmental changes

For more information on sustainability at IFF, visit https://www.iff.com/en/our-purpose/sustainability .

# # #

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye